Paving the Way for Diversity in Clinical Trials

Hala Borno, MD, assistant professor of medicine, Division of Oncology and Hematology, College of California, San Francisco

Jamie Freedman, head of U.S. health-related affairs, Genentech.

Jennifer Jones-McMeans, PhD, director of world-wide medical affairs, Abbott Prescribed drugs.

Marya Shegog, PhD, well being fairness and diversity coordinator, Lazarex Most cancers Foundation.

Andrea Denicoff, registered nurse and nurse specialist, National Most cancers Institute chief of medical trials functions, NCI’s National Clinical Trials Network.

‘Lola Fashoyin-Aje, MD, deputy division director and affiliate director, science and plan to deal with disparities, Oncology Centre of Excellence, Food and drug administration.

Keanna Ghazvini, spokesperson, Pfizer Prescribed drugs.

Food and drug administration: “Drug Trials Snapshots: NINLARO.”

National Most cancers Institute: “NIH Coverage and Pointers on The Inclusion of Gals and Minorities as Topics in Clinical Analysis,” “Inclusion of Gals and Minorities as Members in Analysis Involving Human Topics,” “Cancer Disparities.” “ Qualifications.”

Lazarex Most cancers Foundation.

Genentech Biotechnology Enterprise.

Abbott Laboratories: “Abbott Announces Get started Of Trial To Appraise The New Espri Btk Drug-Eluting Resorbable Scaffold.”

Pfizer Prescribed drugs.

American Most cancers Culture.

American Culture of Clinical Oncology.

Present-day Clinical Trials: “Does the COVID-19 outbreak establish a broader need for an urgent transformation of most cancers medical trials study?”

The New York Occasions: “Clinical Trials Are Going Out of the Lab and Into People’s Houses.”

Massey Most cancers Centre, Virginia Commonwealth College: “First Girl Jill Biden visits Massey to examine most cancers disparities and group engaged study.”

ProPublica: “Black People Pass up Out On Promising Most cancers Medications.”